Department of Biology, University of Waterloo, Waterloo, Ontario, Canada.
Biotechnol Adv. 2012 Sep-Oct;30(5):1119-39. doi: 10.1016/j.biotechadv.2011.09.012. Epub 2011 Sep 24.
The initial focus of recombinant protein production by filamentous fungi related to exploiting the extraordinary extracellular enzyme synthesis and secretion machinery of industrial strains, including Aspergillus, Trichoderma, Penicillium and Rhizopus species, was to produce single recombinant protein products. An early recognized disadvantage of filamentous fungi as hosts of recombinant proteins was their common ability to produce homologous proteases which could degrade the heterologous protein product and strategies to prevent proteolysis have met with some limited success. It was also recognized that the protein glycosylation patterns in filamentous fungi and in mammals were quite different, such that filamentous fungi are likely not to be the most suitable microbial hosts for production of recombinant human glycoproteins for therapeutic use. By combining the experience gained from production of single recombinant proteins with new scientific information being generated through genomics and proteomics research, biotechnologists are now poised to extend the biomanufacturing capabilities of recombinant filamentous fungi by enabling them to express genes encoding multiple proteins, including, for example, new biosynthetic pathways for production of new primary or secondary metabolites. It is recognized that filamentous fungi, most species of which have not yet been isolated, represent an enormously diverse source of novel biosynthetic pathways, and that the natural fungal host harboring a valuable biosynthesis pathway may often not be the most suitable organism for biomanufacture purposes. Hence it is expected that substantial effort will be directed to transforming other fungal hosts, non-fungal microbial hosts and indeed non microbial hosts to express some of these novel biosynthetic pathways. But future applications of recombinant expression of proteins will not be confined to biomanufacturing. Opportunities to exploit recombinant technology to unravel the causes of the deleterious impacts of fungi, for example as human, mammalian and plant pathogens, and then to bring forward solutions, is expected to represent a very important future focus of fungal recombinant protein technology.
最初,丝状真菌的重组蛋白生产主要集中在利用工业菌株(包括曲霉属、木霉属、青霉属和根霉属等)非凡的细胞外酶合成和分泌机制,以生产单一的重组蛋白产品。丝状真菌作为重组蛋白宿主的一个早期被认识到的缺点是它们通常能够产生同源蛋白酶,这些蛋白酶可以降解异源蛋白产物,而防止蛋白水解的策略已经取得了一些有限的成功。人们还认识到,丝状真菌和哺乳动物中的蛋白糖基化模式有很大的不同,因此丝状真菌可能不是生产用于治疗的重组人糖蛋白的最合适的微生物宿主。通过将从生产单一重组蛋白中获得的经验与通过基因组学和蛋白质组学研究产生的新科学信息相结合,生物技术人员现在准备通过使丝状真菌能够表达编码多种蛋白的基因,从而扩展重组丝状真菌的生物制造能力,例如,为生产新的初级或次级代谢物而产生新的生物合成途径。人们认识到,丝状真菌(其中大多数尚未被分离)代表了一种非常多样化的新型生物合成途径的来源,而天然真菌宿主中含有有价值的生物合成途径的物种通常不一定是最适合用于生物制造目的的生物体。因此,预计将投入大量精力来转化其他真菌宿主、非真菌微生物宿主,甚至非微生物宿主,以表达其中一些新型生物合成途径。但是,重组蛋白表达的未来应用将不限于生物制造。利用重组技术来揭示真菌的有害影响的原因的机会,例如作为人类、哺乳动物和植物病原体,然后提出解决方案,有望成为真菌重组蛋白技术的一个非常重要的未来重点。